Understanding how ADAM9 affects the immune response to COVID-19
The Role of ADAM9 in the Innate Immune Response to SARS-CoV-2 Infection
This study is looking at a protein called ADAM9 to see how it affects the immune system's response to COVID-19, with the goal of finding new ways to help people who get very sick from the virus.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11055156 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called ADAM9 in how the body’s immune system responds to SARS-CoV-2, the virus that causes COVID-19. The study aims to uncover the mechanisms behind immune dysfunction that can lead to severe disease, such as acute lung injury and respiratory distress. By examining how ADAM9 influences the immune response, researchers hope to identify new pathways that could be targeted for treatment. The approach includes using animal models to observe the effects of ADAM9 on disease severity and immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced severe COVID-19 symptoms or complications, particularly those with acute respiratory distress.
Not a fit: Patients who have mild or asymptomatic COVID-19 infections may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve immune responses in COVID-19 patients, potentially reducing the severity of the disease.
How similar studies have performed: Previous research has shown that targeting immune pathways can lead to significant improvements in treatment outcomes for viral infections, suggesting that this approach may also be promising for COVID-19.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Bazzone, Lindsey E — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Bazzone, Lindsey E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.